FDA approves Daiichi Sankyo's new first-line AML drug quizartinib with boxed warning for heart disorders - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option for the first time, thanks to the FDA's approval of Vanflyta (quizartinib), Daiichi Sankyo announced late Thursday. Vanflyta has been approved for FLT3-ITD-positive AML…